Related references
Note: Only part of the references are listed.Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections
Alba Ruedas-Lopez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales
Juan Carlos Vazquez-Ucha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China
Min Xu et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
Laura Corbella et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)
Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
Casey Doremus et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins
Michael J. Satlin
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017
Ahmed Babiker et al.
CLINICAL INFECTIOUS DISEASES (2021)
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis
Jiating Liu et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study
Damien Fournier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
Milo Gatti et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
An update on cefepime and its future role in combination with novel beta-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Burcu Isler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study
Jia-Yih Feng et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017
Mark Estabrook et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
Delaney E. Hart et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae
Carolina Venditti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan
Shu-Chen Kuo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
Nicholas Rebold et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
Snehal Palwe et al.
ANTIBIOTICS-BASEL (2021)
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
Jacinda C. Abdul-Mutakabbir et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3
Giusy Tiseo et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Multimodal Interventions to Prevent and Control Carbapenem-Resistant Enterobacteriaceae and Extended-Spectrum β-Lactamase Producer-Associated Infections at a Tertiary Care Hospital in Egypt
Noha A. Kamel et al.
ANTIBIOTICS-BASEL (2021)
Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination
Noor Zaidan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany
Patrice Nordmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump
Maria A. Gomis-Font et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae
Jacqueline Findlay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In Vivo Evolution of GES β-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
Christian M. Gill et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals
Mariana Castanheira et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy
Isabel Barcelo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Simultaneous Infection with Enterobacteriaceae and Pseudomonas aeruginosa Harboring Multiple Carbapenemases in a Returning Traveler Colonized with Candida auris
Ayesha Khan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model
James M. Kidd et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017
James A. Karlowsky et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Olexiy Sagan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
Renee Ackley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
Antonio Vena et al.
CLINICAL INFECTIOUS DISEASES (2020)
Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019
E. Voulgari et al.
EUROSURVEILLANCE (2020)
Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis
Hsiu-Ting Chien et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications
Alberto Enrico Maraolo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Bartolome Moya et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
Cheng Lyu et al.
BMC INFECTIOUS DISEASES (2020)
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
Amir Nutman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Efficacy and safety of colistin loading dose: a meta-analysis
Ioannis Bellos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Xiaojuan Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
Thomas P. Lodise et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3
Sachin S. Bhagwat et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
A Retrospective Whole-Genome Sequencing Analysis of Carbapenem and Colistin-Resistant Klebsiella pneumoniae Nosocomial Strains Isolated during an MDR Surveillance Program
Bernardina Gentile et al.
ANTIBIOTICS-BASEL (2020)
Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates
Mustafa Sadek et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
Jeffrey R. Strich et al.
LANCET INFECTIOUS DISEASES (2020)
In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria
Kamilia Abdelraouf et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Precision Medicine: Steps along the Road to Combat Human Cancer
Samuel F. Nassar et al.
CELLS (2020)
In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Enterobacterales Isolates from South Korea
Taeeun Kim et al.
ANTIBIOTICS-BASEL (2020)
Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism
Ke Ma et al.
MSYSTEMS (2020)
Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing
Bejoy P. Maniara et al.
JOURNAL OF PHARMACY PRACTICE (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance
Soo Jung Son et al.
DRUG DISCOVERY TODAY (2019)
Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development
Sherwin K. B. Sy et al.
CLINICAL PHARMACOKINETICS (2019)
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin
Wonhee So et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria
Cecile Emeraud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
E. -T. Piperaki et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study
Jocelyn Qi-Min Teo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Structural Insights into the Inhibition of the Extended-Spectrum β-Lactamase PER-2 by Avibactam
Melina Ruggiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres
Zeb Khan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone
Jorge Arca-Suarez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance Focusing on β-Lactam/β-Lactamase Inhibitor Combinations
Henrietta Abodakpi et al.
CLINICS IN LABORATORY MEDICINE (2019)
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis
Lorenzo Onorato et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations
Stephanie Ho et al.
CURRENT INFECTIOUS DISEASE REPORTS (2019)
Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
Cornelius J. Clancy et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
Vasilios Athans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial
Yaakov Dickstein et al.
CLINICAL INFECTIOUS DISEASES (2019)
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Jodie C. Hamrick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis
Jin Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam
Cristina De la Calle et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment
Karen P. H. Mattos et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial
Hye Jung Park et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
Kenneth S. Thomson et al.
ANTIBIOTICS-BASEL (2019)
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients
Bahiah Ismail et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2018)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2018)
Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals
L. Papst et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients
James D. Finklea et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy
Nadim G. El Chakhtoura et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae
Adrian Sousa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactann Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Krisztina M. Papp-Wallace et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?
Gregory Balabanian et al.
MICROBIAL DRUG RESISTANCE (2018)
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models
Marguerite L. Monogue et al.
PHARMACOLOGY (2018)
Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study
Ritesh Aggarwal et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2018)
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa
Olga Rodriguez-Nunez et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
Treatment of Infections by OXA-48-Producing Enterobacteriaceae
Adam Stewart et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
Manuel Diaz-Canestro et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2018)
Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016
Irene Galani et al.
EUROSURVEILLANCE (2018)
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
Han Zhong et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand
Thundon Ngamprasertchai et al.
INFECTION AND DRUG RESISTANCE (2018)
Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
Melissa D. Barnes et al.
MBIO (2018)
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates
Marla J. Giddins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study
Demosthenes Makris et al.
INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2018)
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms
Yu Mi Wi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in US Hospitals from 2012 to 2015
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2017)
Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality
Laura J. Rojas et al.
CLINICAL INFECTIOUS DISEASES (2017)
Colistin: still a lifesaver for the 21st century?
Ilias Karaiskos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
Oren Zusman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Adnan Alatoom et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
Anna Both et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae
Zhen Shen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis
Su Young Jung et al.
CRITICAL CARE (2017)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Colistin
Nicolas Gregoire et al.
CLINICAL PHARMACOKINETICS (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Application of Precision Medicine Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient
Rossana Rosa et al.
CLINICAL INFECTIOUS DISEASES (2017)
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam
Yunliang Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Madeline King et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase
Melina Ruggiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)
Sibylle H. Lob et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults A Systematic Review and Meta-analysis
Candela Sole-Lleonart et al.
ANESTHESIOLOGY (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
Patrick Grohs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes
Laurent Poirel et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2016)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center
Samuel L. Aitken et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections
E. Durante-Mangoni et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply precision medicine to antimicrobial chemotherapy?
Federico Perez et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Agents of Last Resort Polymyxin Resistance
Keith S. Kaye et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B
Maria Helena Rigatto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Synergistic combinations of polymyxins
Justin R. Lenhard et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
Jennifer A. Huntington et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study
Kady Phe et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Marco Falcone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Early emergence of mcr-1 in Escherichia coli from food-producing animals
Zhangqi Shen et al.
LANCET INFECTIOUS DISEASES (2016)
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study
Yi-Yun Liu et al.
LANCET INFECTIOUS DISEASES (2016)
Metallo-β-Lactamase (MBL)-Producing Enterobacteriaceae in United States Children
Latania K. Logan et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Rapid Detection of Polymyxin Resistance in Enterobacteriaceae
Patrice Nordmann et al.
EMERGING INFECTIOUS DISEASES (2016)
Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods
Brian C. Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mucin Binding Reduces Colistin Antimicrobial Activity
Johnny X. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
Maria Helena Rigatto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Colistin Resistance Mechanisms in Klebsiella pneumoniae Strains from Taiwan
Yi-Hsiang Cheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013
Douglas J. Biedenbach et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Heteroresistance to Colistin in Klebsiella pneumoniae Associated with Alterations in the PhoPQ Regulatory System
Aurelie Jayol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
A review on colistin nephrotoxicity
Atefeh Ordooei Javan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis
Dong Liu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study
Maria Helena Rigatto et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection
Soon-Ee Cheah et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
Richard A. Alm et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Colistin: How should It Be Dosed for the Critically Ill?
Cornelia B. Landersdorfer et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia
Gul Ruhsar Yilmaz et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2015)
beta-Lactam/beta-Lactamase Inhibitor Combinations: From Then to Now
Kimberly A. Toussaint et al.
ANNALS OF PHARMACOTHERAPY (2015)
Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance
Meredith S. Wright et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae
Laurent Poirel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Resistance to Colistin Associated with a Single Amino Acid Change in Protein PmrB among Klebsiella pneumoniae Isolates of Worldwide Origin
Aurelie Jayol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
Matthieu Boisson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Rujipas Sirijatuphat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
S. D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale
N. Gregoire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
MgrB Inactivation Is a Common Mechanism of Colistin Resistance in KPC-Producing Klebsiella pneumoniae of Clinical Origin
Antonio Cannatelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2014)
In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment
Yoonjung Kim et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates
Ji-Young Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2014)
Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia
Thana Khawcharoenporn et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
David J. Farrell et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study
Abiola Olumuyiwa Olaitan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity
Zakuan Z. Deris et al.
JOURNAL OF ANTIBIOTICS (2014)
Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates
Myung-Jin Choi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance
Elena Lopez-Camacho et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort
L. E. Lopez-Cortes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Combination therapy for carbapenem-resistant Gram-negative bacteria
Mical Paul et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)
Helio S. Sader et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Signal-specific temporal response by the Salmonella PhoP/PhoQ regulatory system
Sun-Yang Park et al.
MOLECULAR MICROBIOLOGY (2014)
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Abiola O. Olaitan et al.
FRONTIERS IN MICROBIOLOGY (2014)
Colistin Resistance in a Clinical Acinetobacter baumannii Strain Appearing after Colistin Treatment: Effect on Virulence and Bacterial Fitness
Rafael Lopez-Rojas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Polymyxin Resistance of Pseudomonas aeruginosa phoQ Mutants Is Dependent on Additional Two-Component Regulatory Systems
Alina D. Gutu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Emanuele Durante-Mangoni et al.
CLINICAL INFECTIOUS DISEASES (2013)
Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
H. Aydemir et al.
EPIDEMIOLOGY AND INFECTION (2013)
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Comparison of a Novel, Rapid Chromogenic Biochemical Assay, the Carba NP Test, with the Modified Hodge Test for Detection of Carbapenemase-Producing Gram-Negative Bacilli
Shawn Vasoo et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Emergence of Colistin-Resistance in Extremely Drug-Resistant Acinetobacter baumannii Containing a Novel pmrCAB Operon During Colistin Therapy of Wound Infections
Emil Lesho et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii
Ilkay Karaoglan et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
PmrB Mutations Promote Polymyxin Resistance of Pseudomonas aeruginosa Isolated from Colistin-Treated Cystic Fibrosis Patients
Samuel M. Moskowitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
Zubair A. Qureshi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
Colistin: new lessons on an old antibiotic
D. Yahav et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Phillip J. Bergen et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients
Zoe E. Athanassa et al.
INTENSIVE CARE MEDICINE (2012)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and β-Lactams in Pseudomonas aeruginosa
Cedric Muller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
PhoQ Mutations Promote Lipid A Modification and Polymyxin Resistance of Pseudomonas aeruginosa Found in Colistin-Treated Cystic Fibrosis Patients
Amanda K. Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Insertion Sequence ISAba11 Is Involved in Colistin Resistance and Loss of Lipopolysaccharide in Acinetobacter baumannii
Jennifer H. Moffatt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid A
Luis A. Arroyo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
S. M. Garonzik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System
Alejandro Beceiro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment
O. Zarkotou et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
A Concise Synthesis of a β-Lactamase Inhibitor
Ian K. Mangion et al.
ORGANIC LETTERS (2011)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model
Phillip J. Bergen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
Matthew E. Falagas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Alterations in Two-Component Regulatory Systems of phoPQ and pmrAB Are Associated with Polymyxin B Resistance in Clinical Isolates of Pseudomonas aeruginosa
Kaddy Barrow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria
D. Plachouras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System
Mark D. Adams et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa
Neethu Abraham et al.
FEMS MICROBIOLOGY LETTERS (2009)
Feedback Inhibition in the PhoQ/PhoP Signaling System by a Membrane Peptide
Andrew M. Lippa et al.
PLOS GENETICS (2009)
The Salmonella PmrAB regulon:: lipopolysaccharide modifications, antimicrobial peptide resistance and more
John S. Gunn
TRENDS IN MICROBIOLOGY (2008)
An undecaprenyl phosphate-aminoarabinose flippase required for polymyxin resistance in Escherichia coli
Aixin Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro Pharmacokinetic/Pharmacodynamic model
Chun-Hong Tan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa
Shinobu Takeda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii
Alex P. Betrosian et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2007)
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Matthew E. Falagas et al.
CRITICAL CARE (2006)
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li et al.
LANCET INFECTIOUS DISEASES (2006)
Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
ME Falagas et al.
CLINICAL INFECTIOUS DISEASES (2005)
Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria
J Li et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate
J Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Collateral damage from cephalosporin or quinolone antibiotic therapy
DL Paterson
CLINICAL INFECTIOUS DISEASES (2004)
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration
J Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The pleiotropic two-component regulatory system PhoP-PhoQ
EA Groisman
JOURNAL OF BACTERIOLOGY (2001)
Share Paper
